表紙
市場調查報告書

德國麻疹:開發中產品分析

Rubella (German Measles) - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 271825
出版日期 內容資訊 英文 40 Pages
訂單完成後即時交付
價格
德國麻疹:開發中產品分析 Rubella (German Measles) - Pipeline Review, H1 2020
出版日期: 2020年05月30日內容資訊: 英文 40 Pages
簡介

德國麻疹,也叫風疹,是急性的接觸傳染性病毒感染疾病。德國麻疹病毒,由感染者的噴嚏和咳嗽的飛沫傳染。有發熱、頭痛、鼻塞和鼻涕、發炎、眼睛充血、關節痛、顱底、頸背部、耳廓後的淋巴節腫大等症狀。

本報告提供德國麻疹的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等相關的系統性資訊。

簡介

  • 調查範圍

德國麻疹概要

治療藥的開發

  • 開發中產品的概要
  • 各企業的開發平台
  • 大學/研究機關所開發的開發平台
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

德國麻疹:治療藥的評估

  • 各給藥途徑
  • 各分子類型

德國麻疹的治療藥開發企業

  • Beijing Minhai Biotechnology Co Ltd
  • Biological E Ltd
  • 第一三共
  • GlaxoSmithKline Plc
  • Indian Immunologicals Ltd
  • Prometheon Pharma LLC
  • Sinovac Biotech Ltd
  • Zydus Cadila Healthcare Ltd

藥物簡介

德國麻疹:暫停中的計劃

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC12230IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rubella - Pipeline Review, H1 2020, provides an overview of the Rubella (Infectious Disease) pipeline landscape.

Rubella also known as the German measles is an acute, contagious viral infection. The rubella virus is transmitted by airborne droplets when infected people sneeze or cough. Symptoms include fever, headache, stuffy or runny nose, inflamed, red eyes, aching joints and enlarged, tender lymph nodes at the base of the skull, the back of the neck and behind the ears.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rubella - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Rubella (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rubella (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rubella (German Measles) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 2, 1, 4 and 2 respectively. Similarly, the Universities portfolio in Phase III stages comprises 2 molecules, respectively.

Rubella (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rubella (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Rubella (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rubella (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rubella (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rubella (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rubella (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rubella (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Rubella (German Measles) - Overview
    • Rubella (German Measles) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Rubella (German Measles) - Therapeutics Assessment
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Rubella (German Measles) - Companies Involved in Therapeutics Development
    • Beijing Minhai Biotechnology Co Ltd
    • Biological E Ltd
    • Cadila Healthcare Ltd
    • Daiichi Sankyo Co Ltd
    • Enesi Pharma Ltd
    • GlaxoSmithKline Plc
    • Indian Immunologicals Ltd
    • Micron Biomedical Inc
    • Sinovac Biotech Ltd
    • Univercells SA
    • Zhongyianke Biotech Co Ltd
  • Rubella (German Measles) - Drug Profiles
    • (measles + mumps + rubella + varicella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + mumps + rubella + varicella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + mumps + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + mumps + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles + rubella) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles [strain Edmonston-Zagreb] + mumps [strain Hosino] + rubella [strain RA 27/3]) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles [strain Edmonstons-Zagreb] + rubella [strain RA-27]) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BK-1601 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rubella vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VN-0102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Rubella (German Measles) - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Rubella (German Measles), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Rubella (German Measles) - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2020
  • Rubella (German Measles) - Pipeline by Biological E Ltd, H1 2020
  • Rubella (German Measles) - Pipeline by Cadila Healthcare Ltd, H1 2020
  • Rubella (German Measles) - Pipeline by Daiichi Sankyo Co Ltd, H1 2020
  • Rubella (German Measles) - Pipeline by Enesi Pharma Ltd, H1 2020
  • Rubella (German Measles) - Pipeline by GlaxoSmithKline Plc, H1 2020
  • Rubella (German Measles) - Pipeline by Indian Immunologicals Ltd, H1 2020
  • Rubella (German Measles) - Pipeline by Micron Biomedical Inc, H1 2020
  • Rubella (German Measles) - Pipeline by Sinovac Biotech Ltd, H1 2020
  • Rubella (German Measles) - Pipeline by Univercells SA, H1 2020
  • Rubella (German Measles) - Pipeline by Zhongyianke Biotech Co Ltd, H1 2020
  • Rubella (German Measles) - Dormant Projects, H1 2020

List of Figures

  • Number of Products under Development for Rubella (German Measles), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020